Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153101 · ClinicalTrials.gov registry record · Phase 4
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 31,546
- Enrollment target
NCT00153101: Completed Phase 4 study, sponsored by Boehringer Ingelheim.
NCT00153101 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 31,546 participants, above the 515-participant average among 9,235 other Phase 4 trials with a reported enrollment target (6025% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00153101, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31,546 participants
- Enrollment target
Study Summary
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Primary Outcome
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
Interventions
- DRUG Ramipril
- DRUG Telmisartan
- DRUG Combination of Telmisartan and Ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31,546 participants |
| Start Date | 2001-11 |
| Phase | Phase 4 |
What the finished NCT00153101 record still lists
NCT00153101 is an interventional study that assigns participants to a tested intervention. Its 31,546 participants enrollment target places it among the larger protocols in the corpus, above the 515-participant average among 9,235 other Phase 4 trials with a reported enrollment target (6025% higher).
The record links to 0 conditions, and to 3 interventions - of which Ramipril is the first listed.
NCT00153101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00153101 about?
NCT00153101 is a clinical study titled "Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.". The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, ...
What is the current status of trial NCT00153101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31,546 participants. The study started on 2001-11.
What interventions are being tested in trial NCT00153101?
The interventions under investigation include: Ramipril (DRUG), Telmisartan (DRUG), Combination of Telmisartan and Ramipril (DRUG).
Who is sponsoring clinical trial NCT00153101?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00153101's enrollment target sits among peer trials
31,546 4th of 2000 higher than 1,997 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07282665 · 32,000 participants · Phase 3
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia